Safety and Efficacy of Convalescent Plasma for Severe COVID-19: Interim Report of a Multicenter Phase II Study from Saudi Arabia

OBJECTIVE: To present the interim findings from a national study investigating the safety and efficacy of convalescent plasma (CP) containing detectable IgG antibodies as a treatment strategy for severe coronavirus disease 2019 (COVID-19). TRIAL DESIGN AND PARTICIPANTS: An open label, two-arm, phase...

Descripción completa

Detalles Bibliográficos
Autores principales: AlShehry, Nawal, Zaidi, Syed Ziauddin A, AlAskar, Ahmed, Al Odayani, Abdurahman, Alotaibi, Jawaher Mubarak, AlSagheir, Ahmed, Al-Eyadhy, Ayman, Balelah, Saud, Salam, Abdul, Zaidi, Abdul Rehman Zia, Alawami, Diea, Alshahrani, Mohammed S., AlMozain, Nour, Abulhamayel, Yem M, Al Qunfoidi, Reem, Alfaraj, Mona, Qushmaq, Nahid, Alansari, Rehab, Dayel, Afra, Elgohary, Ghada, Al Bahrani, Ahmed, Nabhan Abdelhameed, Arwa A., AlZahrani, Hazza Abdullah, Alturkistani, Hanan, AlShehry, Nada, Albalawi, Mohammed Abdulhameed, Elalfy, Ibrahim, Alhumaidan, Hind, Al-Hashmi, Hani
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7839574/
https://www.ncbi.nlm.nih.gov/pubmed/33519339
http://dx.doi.org/10.4103/sjmms.sjmms_731_20

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7839574/
https://www.ncbi.nlm.nih.gov/pubmed/33519339
http://dx.doi.org/10.4103/sjmms.sjmms_731_20

Ejemplares similares